Just out. Ipi/nivo didn’t hit OS in cisplatin ineligible or PD-L1 +ve in 1st line UC in CM901. Surprising? Durva/treme (also -ve) had activity, especially in PD-L1 +ves(HR 0.74, CI 0.6-0.9-not stat tested). Different PD-L1 biomarkers used. Data awaited !! news.bms.com/news/corporate…

Hot off the press!! 🔥 Check out our work on the origins and impact of ecDNA. This was a team effort involving multiple collaborators as one of a three part series on ecDNA in nature

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2 ascopubs.org/doi/10.1200/JC…

We are happy to share with you information about the next CNAPS congress! Save the date: 3-5 December, 2025 in Hong Kong. Check the website for more information & stay connected! cnaps2025.org #cnaps2025 #cfDNA #ctDNA #fragmentomics #liquidbiopsy #genomics #Oncology

Today we launched the "ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy" to collect worldwide data on the use of liquid biopsy in clinical practice! Help us sharing the survey with all the oncologists you know :) docs.google.com/forms/d/e/1FAI…

Progression-free survival says it all! Nivolumab + Ipilimumab outperforms chemo in MSI-H/dMMR metastatic CRC. -changing the game! #ColorectalCancer #Immunotherapy #Oncology NEJM OncoAlert Myriam Chalabi nejm.org/doi/full/10.10…

New preprint medRxiv from our lab describes promising results of a collaborative project led by Clayton Marcinak, developing a multianalyte blood test for detection of pancreatic cancer in patients with high-risk incidental lesions medrxiv.org/content/10.110…

In Clinical Cancer Research In Appendiceal Adenocarcinoma ctDNA shedding is less frequent & at lower levels compared to #crcsm, but detectable ctDNA is linked to worse survival. 13% of patients show actionable mutations. #PrecisionMedicine OncoAlert 🚨 International Society of Liquid Biopsy aacrjournals.org/clincancerres/…

Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST) 🔍 Key Highlights: ✅ctDNA dynamics can predict treatment response earlier than imaging. 📊 ✅Proposed LB-RECIST criteria aim to standardize ctDNA-based response assessment. 📝 ✅A step forward for

Great opportunity here 👇 Advanced Research Scientist The NeoGenomics team in Babraham, Cambridge is looking for motivated scientists with deep molecular biology expertise and a passion for early-phase assay research jobs.jobvite.com/careers/neogen…

🎓PhD Opportunities in Early Cancer Detection! Join us for a fully funded 3.5-year PhD starting Oct 2025 🌟Projects include modelling progression risks in Barrett's Oesophagus 🗓 Apply by 16 Feb 2025 #phdpositions #AcademicTwitter #CancerResearch

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for mCRC with mBRAF V600E 👉BREAKWATER phs-3 👉 ORR 61% vs 40% 👉mDoR 13.9 vs 11.1 mo 👉Evaluation of PFS & OS ongoing ESMO - Eur. Oncology

Are you a bioinformatician looking for an exciting opportunity in Melbourne? Is cancer genomics your passion? Apply now! nature.com/naturecareers/…

I forgot to mention! We're recruiting graduate students to develop the next generation of cancer detection tools. Our lab is ideally located in #Montreal and is affiliated with Centre de recherche du CHUM and École de technologie supérieure ^amazing place to go from innovation ▶️ clinic Apply: tinyurl.com/mwtaesee

KRAS: from undruggable to THIS

Organ preservation dream becoming reality! Neoadjuvant PD-1 blockade led to nonoperative management in 80% of early-stage dMMR solid tumors. 92% recurrence-free survival at 2 years. Surgery was not needed: dignity, function, and hope preserved. NEJM Mithat Gönen

We have a position open for a postdoctoral researcher CRUK National Biomarker Centre . This is a unique opportunity to develop #liquidbiopsy #cfDNA methods to non-invasively analyse colorectal cancer plasticity and response to treatments. The position is part of CRC-STARS. cruknbc.org/vacancy-postdo…

Join our 🧬 #LiquidBiopsy team at Queen Mary University of London’s Blizard Institute as a 🔬 Research Technician. Develop cutting-edge pipelines to extract genetic and epigenetic information from #cfDNA and RNA. 🗓️ Deadline: 24th July ✅ Apply: qmul-jobs.tal.net/vx/mobile-0/ap…

Are you looking for a statistics/ML postdoc? Come to work with Antonis Antoniou and me in the NEMO study, an international collaboration aiming to detect ovarian cancer earlier through cutting-edge multi-omics, funded by the Alliance for Cancer Early Detection. cam.ac.uk/jobs/research-…

ROME study Nature Medicine randomized targeted therapy vs standard of care after molecular analysis (tissue/blood) in pretreated cancer patients across tumors. ⬆️ORR (17.5% vs 10%) & ⬆️PFS HR=0.66, but no OS (HR 0.92). OS feels important despite crossover ~45% . Congrats 🥳